Sexton Biotechnologies raises $5M to accelerate commercialization of Cook Regentec’s bioproduction tools

Growth capital supports current, future innovative product development and commercialization

Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. 

In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.

“The opportunity to work closely with partners of such deep expertise in the cell and gene therapy industry will drive new focus to continue our growth. We appreciate the support of Casdin Capital, a leading healthcare hedge fund focused on making multiple thematic investments in biotech ecosystems including the cell and gene therapy space. We’re also excited for the opportunity to work with BioLife Solutions to leverage their sales and marketing expertise and resources as we work to expand our customer base,” said Sean Werner, president of Sexton Biotechnologies. “This new round of investment gives us additional resources to further develop and support our unique products while strengthening our connections in the thriving Indiana life sciences sector through the relationship with BioCrossroads.”

This website uses cookies to ensure you get the best experience on our website.